Absynth Biologics Announces Appointment of CMO
News May 28, 2012
Absynth Biologics Limited, a company developing vaccines and antibodies to prevent and treat bacterial infections, has appointed James Mond as Chief Medical Officer.
As part of the Absynth management team, Dr Mond will have a pivotal role in directing strategy and managing activities to advance the Company’s vaccine and antibody programmes targeting Staph. aureus (including its drug resistant form MRSA) and in shaping and developing Absynth’s infectious diseases pipeline.
James Mond, has a specific expertise in developing immunological products for the prevention of bacterial infections.
Most recently he was Executive Vice President & Chief Scientific Officer, of Biosynexus, a company focused on developing a monoclonal antibody to prevent staphylococcal infections in the low birth weight infant.
Prior to joining Biosynexus, Dr. Mond worked as a consultant to Virion systems Inc. In this position he oversaw the development of a vaccine technology which the company licensed to GlaxoSmithKline (GSK).
Dr. Mond was instrumental in ensuring the bacterial vaccine program with GSK moved forward, and his scientific insights led to new, patented vaccine technology.
These pediatric vaccines have been commercialized to prevent pneumococcal infections and meningococcal infections in the pediatric population. He has also acted as a consultant to the NIH, FDA, and pharmaceutical companies.
Dr. Mond received his M.D. and Ph.D. degrees from New York University Medical School after which he joined the prestigious laboratory of Immunology under Dr. William Paul at the National Institute of Health.
Dr. Mond is an acknowledged worldwide expert in Immunology with 196 publications in the most prestigious journals and books.
He is a practicing board-certified Internist and Rheumatologist and is currently an adjunct Professor of Medicine at the Uniformed Services University of the Health Sciences in Bethesda.
Fiona Marston, Chief Executive of Absynth Biologics said: “I am delighted to have someone of James experience join Absynth at a time when we are reaching important milestones in our S. aureus programmes and expect to see significant developments in building our R&D pipeline during the next few years. His scientific management capabilities and immunological expertise in bacterial infections will ensure that Absynth is well placed to advance its products through pre-clinical and into clinical development.”
Dr Mond added: “It is a pleasure and honor to join the Absynth team. I have worked in previous years with the founders Professor Simon Foster and Dr Jorge Garcia-Lara and they are outstanding investigators in their field of staphylococcal induced disease. I look forward to developing novel vaccines and antibodies that will protect against serious infections."
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.
Children with atopic dermatitis and food allergy have structural and molecular differences in the top layers of healthy-looking skin near the eczema lesions, whereas children with atopic dermatitis alone do not. Defining these differences may help identify children at elevated risk for developing food allergies.READ MORE